Publication Topic

Patlewicz G, Judson, Paul Friedman K, Wetmore BA, DeVito MJ, Harrill JA, Carstens KE, Houck KA, et al. 2025. Insights derived from testing a library of per- and polyfluoroalkyl substances (PFAS) in a battery of new approach methods (NAMs). J Toxicol Environ Health B online ahead of print July 6; doi: 10.1080/10937404.2025.2521615. PMID: 40619890.

Kenyon EM, DeVito MJ, Patlewicz G, Adams LD, Thomas RS, Ambroso JL, Yang X, Blake JC, et al. 2025. Subchronic toxicity of four per- and polyfluoroalkyl substances by oral exposure in Sprague Dawley rats. Toxics 13(7):524; doi: 10.3390/toxics13070524. PMID: 40710969.

Hughes MF, DeVito MJ, Patlewicz G, Thomas RS, Adams LD, Ambroso JL, Yang X, Upadhyay BG, et al. 2025. Immunotoxicity of four per- and polyfluoroalkyl substances following 28-day oral repeat dosing in rats assessed by the anti-sheep red blood IgM response. Toxics 13(6):490; doi: 10.3390/toxics13060490. PMID: 40559963.

Heintz MM, Buerger AN, Haws LC, East AW, Cullen JM, Thompson CM. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mice. Abstract 3972, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025

Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. 2025. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: A case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci 204(1):96-115; doi: 10.1093/toxsci/kfae152. PMID: 39792025.

Patlewicz G, Judson RS, Williams AJ, Butler T, Barone Jr. S, Carstens K, Cowden J, Dawson JD, et al. 2024. Development of chemical categories for per- and polyfluoroalkyl substances (PFAS) and the proof-of-concept approach to the identification of potential candidates for tiered toxicological testing and human health assessment. Comput Toxicol 131(Sep 1):100327; doi: 10.1016/j.comtox.2024.100327. PMID: 40547594.

Lin HC, Sakolish C, Moyer HL, Carmichael PL, Baltazar MT, Ferguson SS, Stanko JP, Hewitt P, et al. 2024. An in vitro-in silico workflow for predicting renal clearance of PFAS. Toxicol Appl Pharmacol 489(Aug):117015; doi: 10.1016/j.taap.2024.117015. PMID: 38917890.

Judson RS, Smith D, DeVito M, Wambaugh JF, Wetmore BA, Paul Friedman K, Patlewicz G, Thomas RS, et al. 2024. A comparison of in vitro points of departure with human blood levels for per- and polyfluoroalkyl substances (PFAS). Toxics 12(4):271; doi: 10.3390/toxics12040271. PMID: 38668494.

Kougias DG, Killius A, Collins J, Russman E, Maddaloni M. 2024. Per- and polyfluoroalkyl substances (PFAS) in drinking water: A retrospective case series with risk assessments. Chapter 7 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 337–396.

Covell LT, Donnell MT, Keeton KA, Madl AK. Human health risk assessment of per- and polyfluoroalkyl substances (PFAS) in facial cosmetics. Poster presentation P342 at Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024. In: The Toxicologist 198(Late-Breaking S1):233–234, Abstract 5240.

Lin H, Sakolish C, Moyer HL, Ferguson SS, Stanko JP, Carmichael PL, Hewitt P, Hoffmann S, et al. Predicting renal clearance of PFAS with a human kidney proximal tubule tissue chip and a novel physiologically-based kidney model. Abstract 3508, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Shirke AV, Radke EG, Lin C, Blain R, Vetter N, Lemeris C, Hartman P,.., Patlewicz G, et al. 2024. Expanded systematic evidence map for hundreds of per- and polyfluoroalkyl substances (PFAS) and comprehensive PFAS human health dashboard. Environ Health Perspect 132(2):026001; doi: 10.1289/EHP134. PMID: 38319881.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147(Feb):105560; doi: 10.1016/j.yrtph.2024.105560. PMID: 38182014.

Jacobellis M, Bain L, Baldwin W. Disruption of energy homeostasis by PFAS mixtures. Southeastern Society of Toxicology, University of Georgia, Athens, GA, 2023.

Rogers JM, Heintz MM, Thompson CM, Haws LC. 2023. A putative adverse outcome network for neonatal mortality and lower birth weight in rodents: Applicability to per- and polyfluoroalkyl substances and relevance to human health. Birth Defects Res 115(11)1011-1062; doi: 10.1002/bdr2.2185. PMID: 37219003.

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

Richard AM, Lougee R, Adams M, Hidle H, Yang C, Rathman J, Magdziarz T, Bienfait B, Williams AJ, Patlewicz G. 2023. A new CSRML structure-based fingerprint method for profiling and categorizing per- and polyfluoroalkyl substances (PFAS). Chem Res Toxicol 36(3):508–534; doi: 10.1021/acs.chemrestox.2c00403. PMID: 36862450.

Carstens KE, Freudenrich T, Wallace K, Choo S, Carpenter A, Smeltz M, Clifton MS,…, Patlewicz G, et al. 2023. Evaluation of per- and polyfluoroalkyl substances (PFAS) in vitro toxicity testing for developmental neurotoxicity. Chem Res Toxicol 36(3):402–419; doi: 10.1021/acs.chemrestox.2c00344. PMID: 36821828.

Houck K, Paul Friedman K, Feshuk M, Patlewicz G, Smeltz M, Clifton S, Wetmore BA, Velichko S, et al. 2023. Evaluation of 147 perfluoroalkyl substances for immunotoxic and other (patho)physiological activities through phenotypic screening of human primary cells. ALTEX 40(2):248–270; doi: 10.14573/altex.220304. PMID: 36129398.